^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Ostarine (enobosarm) (Selective androgen receptor modulator, Androgen receptor modulator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast Cancer
Published date:
12/14/2020
Excerpt:
Veru Inc...announces the clinical results of the second enobosarm Phase 2 clinical study...enobosarm 9mg oral daily dosing was evaluated in 22 heavily pretreated women who have confirmed AR+/ER+/HER2- metastatic breast cancer...enobosarm demonstrated a clinically meaningful six-month clinical benefit rate (complete responses (CR)+partial responses (PR)+ stable disease (SD)) of 35.3%...
